Key Takeaways
- • Trian Partners, the New York-based activist hedge fund led by Nelson Peltz, has built a stake in Unilever Plc, according to a person familiar with the matter cited by Reuters on January 23, 2022, adding pressure on the consumer goods maker.
- • The stake-building was first reported by the Financial Times; neither the size of the stake nor the date it began was disclosed, and Trian and Unilever both declined to comment.
- • The disclosure follows Unilever's decision earlier in January 2022 to effectively abandon its 50 billion pound (about $68 billion) pursuit of GlaxoSmithKline's consumer healthcare business, which had prompted investor scrutiny of Chief Executive Alan Jope's strategy.
- • Trian's playbook, honed at Procter & Gamble in 2017-2018 through a high-profile proxy fight that led to Peltz joining the board, centers on operational fixes often proposed through white papers.
Summary
Trian Partners, the activist hedge fund founded and led by Nelson Peltz, has built a stake in Unilever Plc, ratcheting up pressure on the London-listed consumer goods company, a person familiar with the matter told Reuters on Sunday, January 23, 2022. The Financial Times, which first reported the development, said the people with knowledge of the stake-building had not provided details on the size of the stake or when it began. Trian and Unilever both declined to comment.
Trian is known for proposing operational improvements at its portfolio companies, frequently through white papers, and presents itself as a constructive partner rather than a corporate raider seeking to break companies apart. The fund's most prominent campaign came in 2017-2018 at Procter & Gamble, where it called for a slew of changes. Peltz was subsequently added to the P&G board following a months-long proxy fight, which at the time was the biggest ever involving a U.S. company. P&G later met some of the fund's demands and announced new financial targets, and Peltz stepped down from the board in 2021.
Unilever, maker of brands including Dove soap and Hellmann's mayonnaise, has come under heightened investor scrutiny after the group earlier this month effectively abandoned its 50 billion pound ($68 billion) pursuit of GlaxoSmithKline's consumer healthcare business. Some analysts described the proposed deal, which would have been among the largest ever on the London market, as unexpected and said it raised questions about Chief Executive Alan Jope's plan for a more gradual shift away from lower-margin goods toward health, beauty and hygiene products. The Trian stake emerges against that backdrop, with the fund's involvement expected to intensify debate over the company's strategic direction.
Trian is known for proposing operational improvements at its portfolio companies, frequently through white papers, and presents itself as a constructive partner rather than a corporate raider seeking to break companies apart. The fund's most prominent campaign came in 2017-2018 at Procter & Gamble, where it called for a slew of changes. Peltz was subsequently added to the P&G board following a months-long proxy fight, which at the time was the biggest ever involving a U.S. company. P&G later met some of the fund's demands and announced new financial targets, and Peltz stepped down from the board in 2021.
Unilever, maker of brands including Dove soap and Hellmann's mayonnaise, has come under heightened investor scrutiny after the group earlier this month effectively abandoned its 50 billion pound ($68 billion) pursuit of GlaxoSmithKline's consumer healthcare business. Some analysts described the proposed deal, which would have been among the largest ever on the London market, as unexpected and said it raised questions about Chief Executive Alan Jope's plan for a more gradual shift away from lower-margin goods toward health, beauty and hygiene products. The Trian stake emerges against that backdrop, with the fund's involvement expected to intensify debate over the company's strategic direction.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.